What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
For a condition like retinitis pigmentosa (RP) - which involves over 150 genes - only one therapy currently exists, leaving 98% of patients without treatment options.
I had the pleasure of catching up with Shankar at JPM Week 2025, where he explained how he is utilising a modifier gene therapy platform to tackle blindness caused by RP, geographic atrophy, and Stargardt disease. I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Allucent are helping small- to mid-sized biotechs stay nimble.
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
